AstraZeneca Beefs Up in Metabolic Disease, Paying $1.2B to Partner on CSPC Obesity & Diabetes Meds
AstraZeneca is increasing its prospects in cardiometabolic illness, paying $1.2 billion to start a partnership on eight applications that embrace ...
AstraZeneca is increasing its prospects in cardiometabolic illness, paying $1.2 billion to start a partnership on eight applications that embrace ...
AstraZeneca is paying CSPC Pharmaceutical Group $110 million up front to tap that China-based biotech’s artificial intelligence-driven technology for discovering ...
Copyright © 2025 Your Health 24 7.
Your Health 24 7 is not responsible for the content of external sites.
Copyright © 2025 Your Health 24 7.
Your Health 24 7 is not responsible for the content of external sites.